Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.
-
We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.
-
Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study drugs and 2090 patients on placebo, met the selection criteria.
-
In total, 994 patients received cholinesterase inhibitor treatment (rivastigmine, n = 495; donepezil, n = 499), and 57.9% of patients completed the study.
-
Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug.
-
Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo.
-
Each matched cohort included 23,386 (semaglutide vs sitagliptin), 22,584 (vs empagliflozin), and 19,206 (vs glipizide) patients.
-
A total of seven studies were included. The forest plot results showed that taking lithium therapy reduced the risk of AD (RR 0.59, 95% confidence interval [CI]: 0.44-0.78) and is also protective in reducing the risk of dementia (RR 0.66, 95% CI: 0.56-0.77).
-
SC gantenerumab at doses of up to 1,200 mg Q4W were well tolerated in participants with mild AD dementia.
-
The overall number of participants enrolled was 192, with a mean (standard deviation) amyloid PET load at baseline of 101.80 (29.80) centiloids.
-
A growing number of investigations are exploring the utility of intranasal insulin as a means of mitigating cognitive decline.
-
The sample was mostly female (65%), White (76%), and 74 years old on average.
-
No significant difference was seen in cognitive and functional decline between early and delayed treatment groups.
-
AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks.
-
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later.
-
Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD.
-
77/100
Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001).
-
A low-dose regimen of prednisone is not useful in the treatment of AD.
-
According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid-beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001).
-
Our analysis found that lecanemab showed significant positive statistical efficacy with respect to cognition, function, and behavior in patients with early AD though the actual clinical significance is yet to be established.
-
Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at-risk NDD populations.
-
Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.
-
This study (registered with PROSPERO, CRD42018085967) compares the efficacy (i.e. pro-cognitive effects) and acceptability of antidiabetic agents for Alzheimer's disease (AD) and mild cognitive impairment (MCI).
-
No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested.
-
The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
From across this topic
9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Treatment strategy for late-life depression
- Integrative Multimodal Subtyping, Risk of Incident Mild Cognitive Impairment, and Differential Cardiometabolic Treatment Effects: A Prospective Cohort Study in the All of Us Research Program
- A contemporary review of obstructive sleep apnea
- Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions
- The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
- Therapeutic strategies for Alzheimer's disease in clinical trials
- Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
- Medical genetics-based drug repurposing for Alzheimer's disease
- The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial